|
Volumn 5, Issue 8, 2004, Pages 757-760
|
When the immune system goes on the attack. Thanks to advances in research, it may soon be easier to diagnose autoimmune diseases earlier, but therapy remains a tricky problem
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADALIMUMAB;
CHEMOKINE;
COMPLEMENTARY RNA;
CYTOKINE;
ETANERCEPT;
IBRITUMOMAB TIUXETAN;
IDEC;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
NATALIZUMAB;
NEUROVAX;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RITUXIMAB;
STEROID;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
VISILIZUMAB;
ANTIGEN PRESENTING CELL;
ANTIINFLAMMATORY ACTIVITY;
ARTICLE;
AUTOIMMUNE DISEASE;
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION;
B LYMPHOCYTE ACTIVATION;
CROHN DISEASE;
CYTOKINE PRODUCTION;
DRUG RECEPTOR BINDING;
DRUG TARGETING;
GENETIC SUSCEPTIBILITY;
HUMAN;
IMMUNOPATHOGENESIS;
INFLAMMATION;
INSULIN DEPENDENT DIABETES MELLITUS;
MULTIPLE SCLEROSIS;
OPPORTUNISTIC INFECTION;
PANCREAS ISLET TRANSPLANTATION;
PRIORITY JOURNAL;
PSORIASIS;
RHEUMATOID ARTHRITIS;
SJOEGREN SYNDROME;
SYSTEMIC LUPUS ERYTHEMATOSUS;
T LYMPHOCYTE ACTIVATION;
ULCERATIVE COLITIS;
AUTOIMMUNE DISEASES;
CELL TRANSPLANTATION;
HUMANS;
IMMUNE SYSTEM;
REMISSION INDUCTION;
GOES;
|
EID: 4444268755
PISSN: 1469221X
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.embor.7400217 Document Type: Article |
Times cited : (9)
|
References (11)
|